Trial Profile
A PHASE II STUDY OF LETROZOLE IN PATIENTS WITH ADVANCED OR RECURRENT ENDOMETRIAL CANCER
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Letrozole (Primary)
- Indications Adenosquamous carcinoma; Endometrial cancer
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 24 Apr 2012 New trial record